Wild-type p53 renders mouse astrocytes resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea despite the absence of a p53-dependent cell cycle arrest

Cancer Research

Volumn 56, Issue 12, 1996, Pages 2748-2751

  Nutt, Catherine L ^a,b   Chambers, Ann F ^a,b   Cairncross, J Gregory ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; PROTEIN P53;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE; GENETIC STABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTES; CARMUSTINE; CELL LINE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; G1 PHASE; G2 PHASE; GENOTYPE; MICE; MICE, KNOCKOUT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029885315     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelslein, B., and Craig, R W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
2. Kuerbitz, S. J., Plunkett, B S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
3. Clarke, A. R., Purdie, C. A., Hamson, D. J., Morris, R. G., Bird, C. C , Hooper, M L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993
4. Lowe, S W., Ruley, H E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell, 74: 957-967, 1993
5. O'Connor, P. M , Jackman, J., Jondle, D., Bhatta, K., Magrath, I , and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993
6. McIlwrath, A. J., Vasey, P. A., Ross, G. M., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines dependence on wild-type p53 for radiosensitivity. Cancer Res , 54: 3718-3722, 1994.
7. Nabeya, Y , Loganzo, F , Jr., Maslak, P., Lai, L., de Oliveira, A. R., Schwartz, G K., Blundell, M L , Altorki, N. K., Kelson, D. P., and Albino, A. P. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int. J. Cancer, 64: 37-46, 1995.
8. Chang, F., Syrjänen, S., and Syrjanen, K Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin. Oncol., 13 1009-1022, 1995.
9. Biard, D. S F., Martin, M , Le Rhun, Y , Duthu, A., Lefaix, J. L., May, E., and May, P Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res., 54: 3361-3364, 1994.
10. Petty, R D., Cree, I. A., Sutherland, L. A., Hunter, E. M., Lane, D P, Preece, P. E., and Andreotti, P. E. Expression of the p53 tumor suppressor gene product is a determinant of chemosensmvity Biochem Biophys Res Commun., 199: 264-270, 1994.
11. Fan, S., Smith, M L., Rivet, D. J , II, Duba, D., Zhan, Q , Kohn, K. W., Fornace, A J , Jr., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55. 1649-1654, 1995.
12. Vikhanskaya, F , D'Incalci, M., and Broggini, M. Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes Int. J Cancer, 61, 397-401, 1995.
13. van Meyel, D. J., Ramsay, D. A., Casson, A G., Keeney, M , Chambers, A. F., and Cairncross, J. G. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst., 86: 1011-1017, 1994.
14. Donehower, L. A., Harvey, M , Slagle, B. L , McArthur, M. J , Montgomery, C. A., Jr , Butel, J. S , and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
15. McCarthy, K. D., and de Vellis, J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol., 85: 890-902, 1980.
16. Timme, T L., and Thompson, T. C Rapid allelotype analysis of p53 knockout mice. BioTechniques, 17: 460-463, 1994.
17. 6-Methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage. Can. J. Neurol. Sci., 22: 111-115, 1995.
18. Brachman, D. G., Beckett, M., Graves, D., Haraf, D , Vokes, E., and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53: 3667-3669, 1993.
19. Slichenmyer, W J., Nelson, W. G., Slebos, R J., and Kastan, M. B. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res , 53: 4164-4168, 1993
20. 2. Nature (Lond.), 254. 245-247, 1975
21. Tobey, R. A., and Crissman, H. A. Comparative effects of three nitrosourea derivatives on mammalian cell cycle progression. Cancer Res., 55: 460-470, 1975
22. Barranco, S. C., and Humphrey, R. M. The effects of 1,3-bis(2-chloroethyl)-1-nitrosourea on survival and cell progression in Chinese hamster cells. Cancer Res , 31 191-195, 1971.
23. Nomura, K., Hoshino, T., Knebel, K., Deen, D. F., and Barker, M. BCNU-induced perturbations in the cell cycle of 9L rat brain tumor cells. Cancer Treat. Rep , 62: 747-754, 1978.
24. Hoshino, T., Deen, D. F., Williams, M. E., and Sano, Y. Differential response of elutriated 9L cells to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res , 41: 4404-4407, 1981
25. Hartwell, L Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71. 543-546, 1992.
26. Janzer, R. C., and Raff, M. C. Ascrocytes induce blood-brain barrier properties in endothelial cells Nature (Lond.), 325: 253-257, 1987.
27. Chung, R., Whaley, J., Kley, N., Anderson, K., Louis, D., Menon, A., Hettlich, C., Freiman, R., Hedley-Whyte, E. T., Martuza, R., Jenkins, R., Yandell, D , and Seizinger, B R. TP53 gene mutations and 17p deletions in human astrocytomas. Genes, Chromosomes & Cancer, 3: 323-331, 1991.
28. Frankel, R. H., Bayona, W., Koslow, M., and Newcomb, E. W. p53 mutations in human malignant guomas: comparison of loss of heterozygosity with mutation frequency Cancer Res., 52: 1427-1433, 1992.
29. Louis, D. N., von Deimling, A , Chung, R. Y., Rubio, M.-P., Whaley, J. M , Eibl, R. H , Ohgaki, H., Wiestler, O. D., Thor, A. D., and Seizinger, B. R. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J. Neuropathol. & Exp. Neurol., 52: 31-38, 1993.
30. Van Meir, E. G., Kikuchi, T., Tada, M. Li, H , Diserens, A -C., Wojcik, B. E., Su Huang, H.-J , Friedmann, T., de Tribolet, N., and Cavenee, W. K. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res., 54: 649-652, 1994
31. Chang, C. H., Horton, J , Schoenfeld, D., Salazer, O., Perez-Tamayo, R., Kramer, S., Weinstein, A., Nelson, J S., and Tsukada, Y. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer (Phila ), 52: 997-1007, 1983.
32. Nelson, D. F , Diener-West, M., Horton, J., Chang, C. H., Schoenfeld, D., and Nelson, J S. Combined modality approach to treatment of malignant gliomas - re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr., 6: 279-284, 1988.
33. Grant, R , Liang, B. C., Page, M. A., Crane, D L., Greenberg, H. S , and Junck, L. Age influences chemotherapy response in astrocytomas. Neurology, 45: 929-933, 1995.
34. o-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. Cancer (Phila ), 75: 1339-1342, 1995